Skip to main content

Articles

Original Research
Prospective Bundled Payments in a Changing Environment: The Experience of a Self-Funded, State-Sponsored Plan
Frank H. Lawler, MD, MSPH; Frank R. Wilson, CPA; G. Keith Smith, MD; Lynn V. Mitchell, MD, MPH
Stakeholder Perspective
Oklahoma Benefits Program Setting an Example: A Cost-Effective Bundled Payments Option for State Employees
James T. Kenney, RPh, MBA
Read More
Original Research, Practice Management
The Effects of a Sitagliptin Formulary Restriction Program on Diabetes Medication Use
Yuexin Tang, PhD; Xingyue Huang, PhD; Jinan Liu, PhD; R. Ravi Shankar MD; Michael L. Ganz, PhD; Swapnil Rajpathak, MD, DrPH
Stakeholder Perspective
Impact of Step Therapy Restrictions in Diabetes Care
Quang T. Nguyen, DO, FACP, FACE, FTOS
Read More
Conference Highlights AMCP
AMCP Nexus 2017 Highlights
Read More
Practice Management
Comparing the Medicaid Retrospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies
Sergio I. Prada, MPA, PhD
Stakeholder Perspective
Is the Federal Drug Utilization Review Requirement Just Red Tape or an Enlightened State of Flexibility?
Michael Kleinrock
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Acalabrutinib with Obinutuzumab in Relapsed/Refractory and Treatment-Naïve Patients with CLL: The Phase 1b/2 ACE-CL-003 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
High Complete Response Rates with Pembrolizumab with Rituximab in Patients with Relapsed FL: Results of an Open-Label, Phase 2 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Efficacy and Safety of Bendamustine and Rituximab as First Salvage Treatment in CLL: Results of the GIMEMA-ERIC LLC1315 Study
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Phase 1/2 Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL
Read More
ASH 2017 - Chronic Lymphocytic Leukemia
Randomized Trial of Ibrutinib versus Ibrutinib plus Rituximab in Patients with CLL
Read More
Page 77 of 245
Results 761 - 770 of 2441